>
CellSource Co logo

4880 - CellSource Co Share Price

¥6800 70.0  1.0%

Last Trade - 1:58am

Sector
Healthcare
Size
Mid Cap
Market Cap £795.7m
Enterprise Value £782.4m
Revenue £16.9m
Position in Universe 695th / 3907
Bullish
Bearish
Unlock 4880 Revenue
Momentum
Relative Strength (%)
1m +8.78%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.47%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Oct 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 519.1 1,213 1,612 1,855 +52.9%
+73.6 +2.4 -6.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 July 2021, CellSourceCo Ltd revenues increased 60% to Y2.1B. Net incomeapplicable to common stockholders increased from Y158.4M toY428.2M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Net income benefited from Other Non-OperatingIncome increase from Y86K to Y3.2M (income), Share issuancecost decrease from Y886K (expense) to Y0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

4880 Revenue Unlock 4880 Revenue

Net Income

4880 Net Income Unlock 4880 Revenue

Normalised EPS

4880 Normalised EPS Unlock 4880 Revenue

PE Ratio Range

4880 PE Ratio Range Unlock 4880 Revenue

Dividend Yield Range

4880 Dividend Yield Range Unlock 4880 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
4880 EPS Forecasts Unlock 4880 Revenue
Profile Summary

CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.

Directors
Last Annual October 31st, 2020
Last Interim July 31st, 2021
Incorporated November 30, 2015
Public Since October 28, 2019
No. of Shareholders: 1,087
No. of Employees: 68
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange Tokyo Stock Exchange
Shares in Issue 6,195,471
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4880 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4880
Upcoming Events for 4880
Thursday 28th October, 2021
Dividend For 4880.T - 0.0000 JPY
Monday 1st November, 2021
CellSource Co Ltd Split For 4880.T - Ratio 3-1
Frequently Asked Questions for CellSource Co
What is the CellSource Co share price?

As of 1:58am, shares in CellSource Co are trading at ¥6800, giving the company a market capitalisation of £795.7m. This share price information is delayed by 15 minutes.

How has the CellSource Co share price performed this year?

Shares in CellSource Co are currently trading at ¥6800 and the price has moved by 0.109k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CellSource Co price has moved by 68.49% over the past year.

What are the analyst and broker recommendations for CellSource Co?

There are no analysts currently covering CellSource Co.

When will CellSource Co next release its financial results?

CellSource Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-07-31
What is the CellSource Co dividend yield?

CellSource Co does not currently pay a dividend.

Does CellSource Co pay a dividend?

CellSource Co does not currently pay a dividend.

When does CellSource Co next pay dividends?

CellSource Co does not currently pay a dividend.

How do I buy CellSource Co shares?

To buy shares in CellSource Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CellSource Co?

Shares in CellSource Co are currently trading at ¥6800, giving the company a market capitalisation of £795.7m.

Where are CellSource Co shares listed? Where are CellSource Co shares listed?

Here are the trading details for CellSource Co:

Country of listing: Japan
Exchange: TYO
Ticker Symbol: 4880
What kind of share is CellSource Co?

Based on an overall assessment of its quality, value and momentum, CellSource Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CellSource Co share price forecast 2021?

We were not able to load any forecast data for CellSource Co.

How can I tell whether the CellSource Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CellSource Co. Over the past six months, the relative strength of its shares against the market has been 67.92%. At the current price of ¥6800, shares in CellSource Co are trading at 46.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CellSource Co PE Ratio?

The CellSource Co PE ratio based on its reported earnings over the past 12 months is 0.238k. The shares are currently trading at ¥6800.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of CellSource Co?

CellSource Co's management team is headed by:

Masato Tsumamoto - PRE
Takeshi Amemiya - CFO
Hirohiko Hanaki - CCO
Norio Murakami - IND
Masaro Nozaki - EXO
Katsuji Ohnishi - EXO
Kenta Fujita - EXO
Who are the major shareholders of CellSource Co?

Here are the top five shareholders of CellSource Co based on the size of their shareholding:

Yamakawa (Masayuki) Individual Investor
Percentage owned: 46.31% (2.87m shares)
Tsumamoto (Masato) Individual Investor
Percentage owned: 12.78% (792k shares)
Serial Incubate KK Corporation
Percentage owned: 10.23% (634k shares)
Asset Management One Co., Ltd. Investment Advisor/Hedge Fund
Percentage owned: 3.34% (207k shares)
AM-One Enterprise Value Growth Small Cap Stock Fund (Ganriki Mutual Fund
Percentage owned: 1.65% (102k shares)
Similar to 4880
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.